CDK4 and breast cancer: In ER+/HER2− breast cancer, CDK4/6, mammalian targets of rapamycin inhibitors, and phosphoinositide 3-kinase inhibitors have substantially improved breast cancer prognosis (Janku et al. 2012, Piccart et al. 2014, Hamilton & Infante 2016).